Aspire Biopharma Holdings, Inc.
ASBP
$0.4871
-$0.0205-4.04%
NASDAQ
| 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | 09/30/2023 | |
|---|---|---|---|---|---|
| Net Income | -48.63% | 0.00% | -113.41% | -17.25% | 39.58% |
| Total Depreciation and Amortization | -- | -- | -- | -- | -- |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -- | -- | -- | -- | -- |
| Change in Net Operating Assets | -596.92% | 0.00% | -86.03% | 276.56% | -278.85% |
| Cash from Operations | -405.97% | 0.00% | -130.91% | 212.90% | -1,359.58% |
| Capital Expenditure | -- | -- | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 300.52% | 0.00% | 74.84% | -298.17% | 300.52% |
| Cash from Investing | 300.52% | 0.00% | 74.84% | -298.17% | 300.52% |
| Total Debt Issued | -- | -- | -- | -200.00% | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -100.00% | 0.00% | -- | -- | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | 282.38% | 0.00% | 147.92% | -200.00% | -- |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -173.81% | 0.00% | 223.53% | -170.83% | -2.04% |